Artemis Medicare Services Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Artemis Medicare Services reported strong full-year FY26 results with standalone revenue from operations growing 16.1% to ₹1,06,049.17 Lacs from ₹91,326.13 Lacs in FY25. Net profit after tax increased 24% to ₹10,344.15 Lacs versus ₹8,345.78 Lacs, driven by higher international revenues (₹32,268 Lacs, up 27% YoY). EBITDA margin compressed to approximately 20% from ~23.3% in the prior year due to higher operative costs and a ₹307.44 Lacs exceptional charge for new Labour Code implementation. Finance costs declined to ₹2,694.40 Lacs from ₹3,048.26 Lacs. The Board recommended a final dividend of ₹0.45 per share (45%) subject to shareholder approval. The company also issued 17,41,750 equity shares under ESOP and converted ₹33,000 Lacs CCDs into equity in November 2025. Auditors issued an unmodified opinion with no going concern issues.
Artemis Medicare delivered ~24% PAT growth and strong revenue expansion, though margin compression warrants attention. The Labour Code impact is non-recurring. Investors may respond positively to the profit growth and dividend, but the compression in EBITDA margins is a key monitorable.